FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI

The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Related Keywords

Tonik Choueiri ,Merck Welireg ,Lank Center ,Dana Farber Cancer Institute ,Genitourinary Cancer At Dana Farber Institute ,Paper Texture ,Araki Illustrations ,Genitourinary Cancer ,Farber Cancer ,Belzutifan ,Renal Cell Carcinoma ,